Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September.

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

10x Genomics has marked a new phase in its remarkable expansion by opening a modern office building that has just sprouted in Pleasanton.

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know.

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. Click here to read more.

10x Genomics slashed its FY24 revenue guidance from $640 million-$5660 million to $595 million-$605 million. 10x Genomics shares gained 6.3% to trade at $16.79 on Wednesday.

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...

A federal judge in Delaware said on Monday that 10x Genomics and Harvard University must face antitrust counterclaims over their licensing practices in two gene-analysis patent lawsuits.

We are grateful to work with Arc and 10x Genomics to advance the development of these resources to accelerate scientific discovery and advance our understanding of biology’s complexity." ...

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.